Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801982 | 0.93 | REN (0.48) | RENACETACR1 | |
| SCHEMBL29801844 | 0.93 | ACE (0.47) | RENACE | |
| SCHEMBL29801697 | 0.92 | ACE (0.47) | RENACE | |
| SCHEMBL29802042 | 0.91 | ACE (0.48) | RENACETACR1 | |
| SCHEMBL29801692 | 0.90 | ACE (0.48) | RENACETACR1 | |
| SCHEMBL30844403 | 0.89 | REN (0.49) | REN | |
| SCHEMBL29777729 | 0.88 | REN (0.48) | RENACE | |
| SCHEMBL30731556 | 0.88 | REN (0.48) | RENACE | |
| SCHEMBL29801925 | 0.88 | REN (0.45) | RENACENTSR2NTSR1 | |
| SCHEMBL29801949 | 0.87 | ACE (0.48) | RENACETACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | REN 197/4885ACE 277/4885TACR1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.